PARP inhibitors serve several roles in cancer treatment, including sensitization to chemotherapy and radiotherapy, synthetic lethality in tumors from patients with hereditary mutations in BRCA1/2 genes, and leveraging of supposed “BRCA-like” defects and defects in DNA repair [44, 46]. Here, BRCA1 is linked to cancer.